165 related articles for article (PubMed ID: 28628770)
1. A comparative analysis between proteasome and immunoproteasome inhibition in cellular and humoral alloimmunity.
Eleftheriadis T; Pissas G; Antoniadi G; Liakopoulos V; Stefanidis I
Int Immunopharmacol; 2017 Sep; 50():48-54. PubMed ID: 28628770
[TBL] [Abstract][Full Text] [Related]
2. In human cell cultures, everolimus is inferior to tacrolimus in inhibiting cellular alloimmunity, but equally effective as regards humoral alloimmunity.
Eleftheriadis T; Pissas G; Sounidaki M; Antoniadi G; Antoniadis N; Liakopoulos V; Stefanidis I
Int Urol Nephrol; 2017 Sep; 49(9):1691-1697. PubMed ID: 28508247
[TBL] [Abstract][Full Text] [Related]
3. Uric acid increases cellular and humoral alloimmunity in primary human peripheral blood mononuclear cells.
Eleftheriadis T; Pissas G; Sounidaki M; Antoniadi G; Antoniadis N; Liakopoulos V; Stefanidis I
Nephrology (Carlton); 2018 Jul; 23(7):610-615. PubMed ID: 28477373
[TBL] [Abstract][Full Text] [Related]
4. Immunoproteasome inhibition induces plasma cell apoptosis and preserves kidney allografts by activating the unfolded protein response and suppressing plasma cell survival factors.
Li J; Koerner J; Basler M; Brunner T; Kirk CJ; Groettrup M
Kidney Int; 2019 Mar; 95(3):611-623. PubMed ID: 30685098
[TBL] [Abstract][Full Text] [Related]
5. Immunoproteasome inhibition prevents chronic antibody-mediated allograft rejection in renal transplantation.
Li J; Basler M; Alvarez G; Brunner T; Kirk CJ; Groettrup M
Kidney Int; 2018 Mar; 93(3):670-680. PubMed ID: 29229189
[TBL] [Abstract][Full Text] [Related]
6. Proteasome or immunoproteasome inhibitors cause apoptosis in human renal tubular epithelial cells under normoxic and hypoxic conditions.
Eleftheriadis T; Pissas G; Antoniadi G; Liakopoulos V; Stefanidis I
Int Urol Nephrol; 2016 Jun; 48(6):907-15. PubMed ID: 26920131
[TBL] [Abstract][Full Text] [Related]
7. Comparison of the effect of the aerobic glycolysis inhibitor dichloroacetate and of the Krebs cycle inhibitor LW6 on cellular and humoral alloimmunity.
Eleftheriadis T; Pissas G; Mavropoulos A; Liakopoulos V; Stefanidis I
Biomed Rep; 2017 Nov; 7(5):439-444. PubMed ID: 29181155
[TBL] [Abstract][Full Text] [Related]
8. Indoleamine 2,3-dioxygenase suppresses humoral alloimmunity via pathways that different to those associated with its effects on T cells.
Sounidaki M; Pissas G; Eleftheriadis T; Antoniadi G; Golfinopoulos S; Liakopoulos V; Stefanidis I
Biomed Rep; 2019 Jun; 1(1):1-5. PubMed ID: 31258898
[TBL] [Abstract][Full Text] [Related]
9. mTOR Inhibition Suppresses Posttransplant Alloantibody Production Through Direct Inhibition of Alloprimed B Cells and Sparing of CD8+ Antibody-Suppressing T cells.
Avila CL; Zimmerer JM; Elzein SM; Pham TA; Abdel-Rasoul M; Bumgardner GL
Transplantation; 2016 Sep; 100(9):1898-906. PubMed ID: 27362313
[TBL] [Abstract][Full Text] [Related]
10. Beneficial effect of novel proteasome inhibitors in murine lupus via dual inhibition of type I interferon and autoantibody-secreting cells.
Ichikawa HT; Conley T; Muchamuel T; Jiang J; Lee S; Owen T; Barnard J; Nevarez S; Goldman BI; Kirk CJ; Looney RJ; Anolik JH
Arthritis Rheum; 2012 Feb; 64(2):493-503. PubMed ID: 21905015
[TBL] [Abstract][Full Text] [Related]
11. Assessment of Humoral Alloimmunity in Mixed Lymphocyte Reaction.
Pissas G; Eleftheriadis T
Bio Protoc; 2019 Jan; 9(2):e3139. PubMed ID: 33654885
[TBL] [Abstract][Full Text] [Related]
12. Proteasome inhibition for antibody-mediated rejection.
Everly JJ; Walsh RC; Alloway RR; Woodle ES
Curr Opin Organ Transplant; 2009 Dec; 14(6):662-6. PubMed ID: 19667989
[TBL] [Abstract][Full Text] [Related]
13. Bortezomib for refractory acute antibody-mediated rejection in kidney transplant recipients: A single-centre case series.
De Sousa-Amorim E; Revuelta I; Diekmann F; Cofan F; Lozano M; Cid J; Palou E; Sole M; Campistol JM; Oppenheimer F
Nephrology (Carlton); 2016 Aug; 21(8):700-4. PubMed ID: 26492594
[TBL] [Abstract][Full Text] [Related]
14. Proteasome inhibition for recipient desensitization? A report of two sensitized kidney transplant candidates subjected to bortezomib treatment.
Wahrmann M; Haidinger M; Drach J; Geyeregger R; Kikić Z; Raab R; Säemann MD; Böhmig GA
Clin Transpl; 2009; ():415-20. PubMed ID: 20524307
[TBL] [Abstract][Full Text] [Related]
15. No prolongation of skin allograft survival by immunoproteasome inhibition in mice.
Mundt S; Basler M; Sawitzki B; Groettrup M
Mol Immunol; 2017 Aug; 88():32-37. PubMed ID: 28582644
[TBL] [Abstract][Full Text] [Related]
16. [Proteasome inhibitors in cancer therapy].
Romaniuk W; Ołdziej AE; Zińczuk J; Kłoczko J
Postepy Hig Med Dosw (Online); 2015 Dec; 69():1443-50. PubMed ID: 27259216
[TBL] [Abstract][Full Text] [Related]
17. In Mixed Lymphocyte Reaction, the Hypoxia-Inducible Factor Prolyl-Hydroxylase Inhibitor Roxadustat Suppresses Cellular and Humoral Alloimmunity.
Eleftheriadis T; Pissas G; Mavropoulos A; Nikolaou E; Filippidis G; Liakopoulos V; Stefanidis I
Arch Immunol Ther Exp (Warsz); 2020 Oct; 68(6):31. PubMed ID: 33011826
[TBL] [Abstract][Full Text] [Related]
18. Effect of the proteasome inhibitor bortezomib on humoral immunity in two presensitized renal transplant candidates.
Wahrmann M; Haidinger M; Körmöczi GF; Weichhart T; Säemann MD; Geyeregger R; Kikić Z; Prikoszovich T; Drach J; Böhmig GA
Transplantation; 2010 Jun; 89(11):1385-90. PubMed ID: 20335829
[TBL] [Abstract][Full Text] [Related]
19. Inhibiting the immunoproteasome's β5i catalytic activity affects human peripheral blood-derived immune cell viability.
Pletinckx K; Vaßen S; Schlusche I; Nordhoff S; Bahrenberg G; Dunkern TR
Pharmacol Res Perspect; 2019 Aug; 7(4):e00482. PubMed ID: 31236277
[TBL] [Abstract][Full Text] [Related]
20. Pre-clinical evaluation of proteasome inhibitors for canine and human osteosarcoma.
Patatsos K; Shekhar TM; Hawkins CJ
Vet Comp Oncol; 2018 Dec; 16(4):544-553. PubMed ID: 29998615
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
